🎉 M&A multiples are live!
Check it out!

C4 Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for C4 Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Julphar.

C4 Therapeutics Overview

About C4 Therapeutics

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.


Founded

2015

HQ

United States of America
Employees

110

Financials

LTM Revenue $32.3M

LTM EBITDA -$110M

EV

-$91.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

C4 Therapeutics Financials

C4 Therapeutics has a last 12-month revenue of $32.3M and a last 12-month EBITDA of -$110M.

In the most recent fiscal year, C4 Therapeutics achieved revenue of $35.6M and an EBITDA of -$103M.

C4 Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See C4 Therapeutics valuation multiples based on analyst estimates

C4 Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $20.8M $35.6M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$128M -$103M XXX XXX XXX
EBITDA Margin -616% -290% XXX XXX XXX
Net Profit -$128M -$132M XXX XXX XXX
Net Margin -618% -372% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

C4 Therapeutics Stock Performance

As of April 15, 2025, C4 Therapeutics's stock price is $1.

C4 Therapeutics has current market cap of $87.3M, and EV of -$91.8M.

See C4 Therapeutics trading valuation data

C4 Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$91.8M $87.3M XXX XXX XXX XXX $-1.60

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

C4 Therapeutics Valuation Multiples

As of April 15, 2025, C4 Therapeutics has market cap of $87.3M and EV of -$91.8M.

C4 Therapeutics's trades at -2.8x LTM EV/Revenue multiple, and 0.8x LTM EBITDA.

Analysts estimate C4 Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for C4 Therapeutics and 10K+ public comps

C4 Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$91.8M XXX XXX XXX
EV/Revenue -2.6x XXX XXX XXX
EV/EBITDA 0.9x XXX XXX XXX
P/E -0.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get C4 Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

C4 Therapeutics Valuation Multiples

C4 Therapeutics's NTM/LTM revenue growth is -17%

C4 Therapeutics's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $1.4M for the same period.

Over next 12 months, C4 Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate C4 Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for C4 Therapeutics and other 10K+ public comps

C4 Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 71% XXX XXX XXX XXX
EBITDA Margin -290% XXX XXX XXX XXX
EBITDA Growth -19% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -308% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $1.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 118% XXX XXX XXX XXX
R&D Expenses to Revenue 311% XXX XXX XXX XXX
Opex to Revenue 429% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

C4 Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Small Molecules comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

C4 Therapeutics M&A and Investment Activity

C4 Therapeutics acquired  XXX companies to date.

Last acquisition by C4 Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . C4 Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by C4 Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About C4 Therapeutics

When was C4 Therapeutics founded? C4 Therapeutics was founded in 2015.
Where is C4 Therapeutics headquartered? C4 Therapeutics is headquartered in United States of America.
How many employees does C4 Therapeutics have? As of today, C4 Therapeutics has 110 employees.
Who is the CEO of C4 Therapeutics? C4 Therapeutics's CEO is Mr. Andrew J. Hirsch.
Is C4 Therapeutics publicy listed? Yes, C4 Therapeutics is a public company listed on NAS.
What is the stock symbol of C4 Therapeutics? C4 Therapeutics trades under CCCC ticker.
When did C4 Therapeutics go public? C4 Therapeutics went public in 2020.
Who are competitors of C4 Therapeutics? Similar companies to C4 Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of C4 Therapeutics? C4 Therapeutics's current market cap is $87.3M
What is the current revenue of C4 Therapeutics? C4 Therapeutics's last 12-month revenue is $32.3M.
What is the current EBITDA of C4 Therapeutics? C4 Therapeutics's last 12-month EBITDA is -$110M.
What is the current EV/Revenue multiple of C4 Therapeutics? Current revenue multiple of C4 Therapeutics is -2.8x.
What is the current EV/EBITDA multiple of C4 Therapeutics? Current EBITDA multiple of C4 Therapeutics is 0.8x.
What is the current revenue growth of C4 Therapeutics? C4 Therapeutics revenue growth between 2023 and 2024 was 71%.
Is C4 Therapeutics profitable? Yes, C4 Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.